Clinical trial
A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer
NCT00078260 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00078260 |
|---|---|
| Title | A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer |
| Official title | A Randomized Phase 3 Study of Two Doses of Alimta in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed |
| Enrollment | 589 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2006 |
| Completion | Apr 1, 2008 |
| First posted | Feb 24, 2004 |
| Last update posted | Sep 12, 2019 |
| Countries | Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: